Lower steroid use in active lupus kidney inflammation
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 80
- You have lupus (systemic lupus erythematosus) diagnosed by standard criteria
- Your kidney disease is biopsy-confirmed proliferative lupus nephritis (class III or IV, sometimes with class V)
- Your kidney function fits one of these: eGFR over 30, or 15–30 with low long-term scarring (NIH chronicity index under 6)
- You can safely take medicines like methylprednisolone, mycophenolate, mouth steroids, or rituximab (no major contraindications)
- You can give informed consent and are able to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.